NZ593694A - Topically active steroids for use in radiation and chemotherapeutics injury - Google Patents

Topically active steroids for use in radiation and chemotherapeutics injury

Info

Publication number
NZ593694A
NZ593694A NZ593694A NZ59369409A NZ593694A NZ 593694 A NZ593694 A NZ 593694A NZ 593694 A NZ593694 A NZ 593694A NZ 59369409 A NZ59369409 A NZ 59369409A NZ 593694 A NZ593694 A NZ 593694A
Authority
NZ
New Zealand
Prior art keywords
medicament
radiation
chemotherapeutics
patient
beclomethasone
Prior art date
Application number
NZ593694A
Other languages
English (en)
Inventor
Robert N Brey
George B Mcdonald
Christopher Schaber
Original Assignee
Soligenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soligenix Inc filed Critical Soligenix Inc
Publication of NZ593694A publication Critical patent/NZ593694A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NZ593694A 2008-12-08 2009-12-08 Topically active steroids for use in radiation and chemotherapeutics injury NZ593694A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12078508P 2008-12-08 2008-12-08
PCT/US2009/067199 WO2010077681A1 (en) 2008-12-08 2009-12-08 Topically active steroids for use in radiation and chemotherapeutics injury

Publications (1)

Publication Number Publication Date
NZ593694A true NZ593694A (en) 2013-09-27

Family

ID=42310112

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ593694A NZ593694A (en) 2008-12-08 2009-12-08 Topically active steroids for use in radiation and chemotherapeutics injury

Country Status (12)

Country Link
US (3) US20100183749A1 (enExample)
EP (2) EP2902031B1 (enExample)
JP (2) JP5709266B2 (enExample)
KR (2) KR20110092351A (enExample)
CN (2) CN102307466A (enExample)
AU (1) AU2009333538B2 (enExample)
CA (1) CA2745930C (enExample)
DK (2) DK2373160T3 (enExample)
IL (1) IL213411A (enExample)
NZ (1) NZ593694A (enExample)
SG (2) SG10201704531XA (enExample)
WO (1) WO2010077681A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
US9017644B2 (en) 2008-11-07 2015-04-28 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
PL3441458T3 (pl) 2009-02-03 2023-11-06 Koninklijke Nederlandse Akademie Van Wetenschappen Podłoże do hodowli nabłonkowych komórek macierzystych i organoidów zawierających wspomniane komórki macierzyste
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US8912323B2 (en) 2009-10-30 2014-12-16 The Regents Of The University Of Michigan Multifunctional small molecules
WO2012112791A1 (en) * 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
WO2013085718A1 (en) 2011-12-08 2013-06-13 The Regents Of The University Of Michigan Multifunctional small molecules
EP2854850B1 (en) * 2012-05-25 2021-05-26 Sloan Kettering Institute For Cancer Research Compositions for treating or preventing radiation disease and gi syndrome
US20160074400A1 (en) * 2012-08-06 2016-03-17 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
WO2014059068A1 (en) * 2012-10-11 2014-04-17 The Trustees Of The University Of Pennsylvania Methods for the treatment and prevention of osteoporosis and bone-related disorders
US9827290B2 (en) 2013-02-28 2017-11-28 The Regents Of The University Of Michigan Compositions and methods relating to induction of intestinal stem cell homeogenesis and/or regeneration
US9850279B2 (en) * 2013-09-13 2017-12-26 Soligenix, Inc. Peptides and analogs for use in the treatment of oral mucositis
US11311598B2 (en) 2013-09-13 2022-04-26 Soligenix, Inc. Peptides and analogs for use in the treatment of oral mucositis
US9439947B2 (en) 2014-03-28 2016-09-13 Albert Einstein College Of Medicine, Inc. Therapy for radiation-induced lung injury
ES3035970T3 (en) * 2014-10-02 2025-09-11 Cytosorbents Corp Use of gastrointestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
WO2017011457A1 (en) * 2015-07-12 2017-01-19 The University Of Tennessee Research Foundation Compositions and methods for protecting colonic epithelial barrier function
WO2017119988A2 (en) * 2015-12-10 2017-07-13 Memorial Sloan Kettering Cancer Center Radioprotection by wnt activation
CN107753932A (zh) * 2016-08-22 2018-03-06 中国辐射防护研究院 Kgf在制备治疗或预防放射性肠炎药物中的用途
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661509A (en) * 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
WO2001024812A1 (en) * 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
US20020086857A1 (en) * 2000-09-15 2002-07-04 Mcdonald George B. Method of long-term treatment of graft-versus-host disease using topical active corticosterioids
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
CA2441007C (en) * 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
CN101060848B (zh) * 2004-12-30 2011-06-22 索利吉尼克斯公司 用二丙酸倍氯米松和泼尼松治疗移植物抗宿主病和白血病
JP4839436B2 (ja) * 2005-11-02 2011-12-21 国立大学法人徳島大学 消化管粘膜保護剤、カベオリン遺伝子発現促進剤及び抗ストレス剤
US20070293458A1 (en) 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
US20080233088A1 (en) * 2007-02-16 2008-09-25 Varian Medical Systems Technologies, Inc. Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation
DK3354276T3 (da) * 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation

Also Published As

Publication number Publication date
EP2373160A4 (en) 2012-06-13
JP5709266B2 (ja) 2015-04-30
JP2015038155A (ja) 2015-02-26
DK2373160T3 (en) 2018-01-02
IL213411A0 (en) 2011-07-31
EP2373160B1 (en) 2017-10-25
CN102307466A (zh) 2012-01-04
IL213411A (en) 2016-12-29
US20200155571A1 (en) 2020-05-21
JP5905562B2 (ja) 2016-04-20
KR101783577B1 (ko) 2017-09-29
CA2745930A1 (en) 2010-07-08
KR20170001735A (ko) 2017-01-04
SG171997A1 (en) 2011-07-28
EP2902031A1 (en) 2015-08-05
CA2745930C (en) 2017-05-02
DK2902031T3 (en) 2019-01-14
KR20110092351A (ko) 2011-08-17
US20170333448A1 (en) 2017-11-23
US20100183749A1 (en) 2010-07-22
CN106692162A (zh) 2017-05-24
EP2902031B1 (en) 2018-10-24
AU2009333538B2 (en) 2014-09-11
SG10201704531XA (en) 2017-07-28
JP2012511034A (ja) 2012-05-17
WO2010077681A1 (en) 2010-07-08
AU2009333538A1 (en) 2011-07-14
EP2373160A1 (en) 2011-10-12
HK1207582A1 (en) 2016-02-05

Similar Documents

Publication Publication Date Title
NZ593694A (en) Topically active steroids for use in radiation and chemotherapeutics injury
NZ604029A (en) Methods of treating bladder cancer
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
WO2012079092A3 (en) Testosterone undecanoate compositions
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
JP2012511034A5 (enExample)
WO2010033188A3 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
MX2014004548A (es) Metodos para tratar pacientes pediatricos usando dexmedetomidina.
JP2015038155A5 (enExample)
WO2007081773A3 (en) Treatment of fatty liver
JP5897164B2 (ja) 外用組成物
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
WO2012117257A8 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
MX2011000319A (es) Uso de rifalazil para tratar trastornos colonicos.
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
RU2009107068A (ru) Применение пропиленгликоля при лечении связанных с воспалением местных нарушений или заболеваний и ран
Singh et al. Iodoform: a boon in disguise
CN106163280A (zh) 小檗碱制剂及其用途
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
JP2013523628A5 (enExample)
Gülnahar et al. Effect of preemptive intravenous ibuprofen on postoperative edema and trismus in third molar tooth extraction: A randomized controlled study
CN104337916A (zh) 一种手脚冰凉及脚气的中药药剂
PH12015502274B1 (en) Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx
JP2016520114A5 (enExample)

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SOLIGENIX, INC., US

Free format text: OLD OWNER(S): SOLIGENIX, INC.; ROBERT N BREY; GEORGE B MCDONALD; CHRISTOPHER SCHABER

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO APPLICANT (71) CHAIN OF TITLE AND INVENTORS (72)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 DEC 2016 BY AJ PARK

Effective date: 20140128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2017 BY COMPUTER PACKAGES INC

Effective date: 20161118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2018 BY COMPUTER PACKAGES INC

Effective date: 20171118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2019 BY COMPUTER PACKAGES INC

Effective date: 20181120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2020 BY COMPUTER PACKAGES INC

Effective date: 20191119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2021 BY COMPUTER PACKAGES INC

Effective date: 20201118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2022 BY COMPUTER PACKAGES INC

Effective date: 20211117

LAPS Patent lapsed